| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.fermentabiotech.com | |
| Market Cap | 333.01 Cr. | |
| Enterprise Value(EV) | 535.15 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -13.62 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 32.00 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 109.01 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 1.04 | Calculated using Price: 113.15 |
| Dividend Yield | 1.10 | Period Ending 2022-03 |
| No. of Shares Subscribed | 2.94 Cr. | 29,430,987 Shares |
| FaceValue | 5 | |
| Company Profile | ||
| Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic. | ||
| 1 Day |
|
-8.08% |
| 1 Week |
|
-14.15% |
| 1 Month |
|
-13.92% |
| 3 Month |
|
-35.96% |
| 6 Month |
|
-45.42% |
| 1 Year |
|
-46.21% |
| 2 Year |
|
-55.50% |
| 5 Year |
|
-52.47% |
| 10 Year |
|
+178.49% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 8.47 | 0.72 | 2.08 | -6.00 | 40.79 | 64.77 | 21.92 | 13.05 | 4.27 | |
| Return on Capital Employed (%) | 10.54 | 3.68 | 6.18 | 1.96 | 33.86 | 40.16 | 12.98 | 12.62 | 7.50 | |
| Return on Assets (%) | 4.55 | 0.37 | 0.99 | -2.76 | 15.85 | 25.73 | 10.75 | 6.56 | 2.04 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 133 | 132 | 130 | 144 | 124 | 251 | 309 | 361 | 372 | 358 | |
| Non Curr. Liab. | 33 | 14 | 24 | 48 | 146 | 125 | 72 | 131 | 154 | 112 | |
| Curr. Liab. | 71 | 94 | 108 | 86 | 104 | 156 | 195 | 230 | 228 | 203 | |
| Minority Int. | 22 | 22 | 26 | 28 | 11 | 0 | 0 | 0 | -1 | -1 | |
| Equity & Liab. | 259 | 262 | 288 | 307 | 385 | 532 | 576 | 722 | 753 | 671 | |
| Non Curr. Assets | 145 | 171 | 195 | 203 | 202 | 226 | 292 | 391 | 419 | 367 | |
| Curr. Assets | 114 | 91 | 93 | 104 | 182 | 296 | 284 | 330 | 335 | 304 | |
| Misc. Exp. not W/O | 10 | ||||||||||
| Total Assets | 259 | 262 | 288 | 307 | 385 | 532 | 576 | 722 | 753 | 671 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 139 | 142 | 155 | 164 | 303 | 405 | 293 | 377 | 399 | 341 | |
| Other Income | 3 | 0 | 1 | 3 | 11 | 27 | 14 | 8 | 8 | 9 | |
| Total Income | 142 | 142 | 156 | 167 | 314 | 431 | 307 | 386 | 407 | 350 | |
| Total Expenditure | -113 | -126 | -135 | -152 | -212 | -269 | -229 | -295 | -336 | -325 | |
| PBIDT | 30 | 16 | 21 | 15 | 102 | 162 | 79 | 91 | 70 | 26 | |
| Interest | -5 | -5 | -6 | -10 | -14 | -21 | -20 | -19 | -18 | -19 | |
| Depreciation | -10 | -9 | -8 | -10 | -12 | -12 | -15 | -20 | -26 | -29 | |
| Taxation | -3 | -2 | -4 | -3 | -21 | -11 | 16 | -9 | -12 | 0 | |
| Exceptional Items | -19 | ||||||||||
| PAT | 11 | 1 | 3 | -8 | 55 | 118 | 60 | 43 | 15 | -41 | |
| Minority Interest | -2 | 0 | -3 | -3 | -13 | 0 | 0 | 3 | 0 | 1 | |
| Share Associate | -1 | 0 | -1 | 0 | -8 | 0 | |||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 8 | 0 | -1 | -11 | 34 | 117 | 60 | 46 | 15 | -40 | |
| Adjusted EPS | 3 | 0 | 0 | -4 | 12 | 43 | 21 | 16 | 5 | -14 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 23 | 14 | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | |
| Cash Fr. Inv. | -20 | -25 | -18 | -13 | 7 | -101 | -97 | -44 | -42 | -26 | |
| Cash Fr. Finan. | -8 | 13 | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | |
| Net Change | -4 | 2 | -2 | 1 | -4 | 47 | 6 | -57 | 20 | -4 | |
| Cash & Cash Eqvt | 4 | 6 | 3 | 5 | -15 | 32 | 38 | -18 | 2 | -2 |
|
Tue, 28 Mar 2023
Execution Of Sale Deed Further to our earlier intimation dated June 9 2022 in relation to the members approval obtained to sell lease or otherwise dispose of the portion of Companys assets being premises located in Thane One Building DIL Complex Ghodbunder Road Majiwade Thane (West) 400 610 we wish to inform you that the Company has executed and registered a sale deed on March 28 2023 to sell premises situated at the 8th floor in Thane One Building DIL Complex Ghodbunder Road Majiwade Thane (West) 400 610 on the terms and conditions mentioned in the sale deed and as approved by the Board of Directors of the Company.The information regarding the aforesaid sale of premises is provided in Annex-A herewith.This intimation is given under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for your records. |
|
Tue, 21 Mar 2023
Execution Of Sale Deed Further to our earlier intimation dated June 9 2022 in relation to the members approval obtained to sell lease or otherwise dispose of the portion of Companys assets being premises located in Thane One Building DIL Complex Ghodbunder Road Majiwade Thane (West) 400 610 we wish to inform you that the Company has executed and registered a sale deed on March 17 2023 to sell premises situated at the 9th floor in Thane One Building DIL Complex Ghodbunder Road Majiwade Thane (West) 400 610 on the terms and conditions mentioned in the sale deed and as approved by the Board of Directors of the Company.The information regarding the aforesaid sale of premises is provided in Annex-A herewith.This intimation is given under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for your records. |
|
Fri, 24 Feb 2023
Intimation Regarding The Composite Scheme Of Amalgamation And Arrangement Amongst DVK Investments Private Limited ('Transferor Company 1') And Aegean Properties Limited ('Transferor Company 2') And Fermenta Biotech Limited ('Transferee Company') And Their Respective Shareholders Under Sections 230 To 232 Of The Companies Act 2013 ('Scheme') Filed Before The Hon'Ble National Company Law Tribunal Mumbai Bench With reference to the captioned subject we would like to inform you that our matter was listed today for final hearing. We are pleased to inform you that our matter was heard by the National Company Law Tribunal Mumbai Bench (NCLT). However we await the further instructions from Honble NCLT in this regard.We request you to kindly take the above information on record. |
| Tue, 28 Mar 2023 |
High Delivery Percentage
|
Close Crossing 52 Week Low
|
Opening at High
|
Closing Below Previous Low
|
Close Within 52 Week Low Zone
|
Equities
M.F.
Sectors